Key facts
- Pluto Bioinformatics’s last known valuation is $21.0M (May 2025).
- It has raised $8.3M; the latest was Seed Round ($3.6M) in May 2025.
- Notable investors include Kickstart (US), Silverton Partners, Harvard University, BioTools Innovator, Wyss Institute at Harvard University.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pluto Bioinformatics
- ·The full record, as it builds
Funding rounds
No funding rounds for Pluto Bioinformatics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pluto Bioinformatics
Developer of a life sciences platform designed for biological data management, analysis, and visualization. The company's platform integrates secure data management, cloud computing and storage, collaborative workflows, no-code computational biology pipelines, multi-omics data upload and visualization, API and integrations support, curated datasets, research assistants, customizable plots, and reproducible sharing features, enabling life sciences researchers to visualize and analyze complex biological data sets efficiently, with no coding required.
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2020
- Employees
- 9
- Website
- pluto.bio/
- Ownership
- Privately Held (backing)
Pluto Bioinformatics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pluto Bioinformatics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pluto Bioinformatics in its N-PORT filings yet. We sweep new filings monthly.